Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".
作者信息
Newall A T, Jit M, Hutubessy R
机构信息
School of Public Health and Community Medicine, Faculty of Medicine, UNSW Australia, Sydney, NSW, 2052, Australia,
出版信息
Pharmacoeconomics. 2014 Dec;32(12):1247. doi: 10.1007/s40273-014-0232-0.
PMID:25374292
Abstract
摘要
相似文献
1
Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".作者对甘乔尔的回复：“当前中低收入国家的成本效益阈值有用吗？来自疫苗领域的例子”。
Pharmacoeconomics. 2014 Dec;32(12):1247. doi: 10.1007/s40273-014-0232-0.
2
Comment on: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".关于《中低收入国家当前的成本效益阈值是否有用？疫苗领域的实例》的评论
Pharmacoeconomics. 2014 Dec;32(12):1245-6. doi: 10.1007/s40273-014-0221-3.
3
Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.当前中低收入国家的成本效益阈值有用吗？来自疫苗领域的例子。
Pharmacoeconomics. 2014 Jun;32(6):525-31. doi: 10.1007/s40273-014-0162-x.
4
Authors' reply to Gandjour: "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany".作者对甘乔尔的回复：“德国肺炎球菌结合疫苗婴儿接种的成本效益建模”
Eur J Health Econ. 2018 Apr;19(3):473-481. doi: 10.1007/s10198-018-0956-4. Epub 2018 Feb 21.
5
[Criteria for introducing new vaccines into the vaccination calendar].[将新疫苗纳入疫苗接种计划的标准]
Rev Esp Quimioter. 2007 Mar;20(1):131-42.
6
Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.轮状病毒疫苗 RIX4414（罗特律®）：在发展中国家预防轮状病毒胃肠炎的药物经济学评价。
Pharmacoeconomics. 2011 Nov;29(11):989-1009. doi: 10.2165/11207210-000000000-00000.
7
8
GAVI gears up for record replenishment.全球疫苗免疫联盟（GAVI）为创纪录的资金补充做准备。
Lancet. 2014 Jul 19;384(9939):219-20. doi: 10.1016/s0140-6736(14)61196-x.
9
Bioterrorism: what level is the threat and are vaccines the answer?生物恐怖主义：威胁程度如何，疫苗能否应对？
Expert Rev Vaccines. 2004 Oct;3(5):493-5. doi: 10.1586/14760584.3.5.493.
10
Status of HPV vaccine introduction and barriers to country uptake.HPV 疫苗接种状况及国家引入的障碍。
Vaccine. 2018 Aug 6;36(32 Pt A):4761-4767. doi: 10.1016/j.vaccine.2018.02.003. Epub 2018 Mar 23.
本文引用的文献
1
Comment on: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".关于《中低收入国家当前的成本效益阈值是否有用？疫苗领域的实例》的评论
Pharmacoeconomics. 2014 Dec;32(12):1245-6. doi: 10.1007/s40273-014-0221-3.
2
Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.当前中低收入国家的成本效益阈值有用吗？来自疫苗领域的例子。
Pharmacoeconomics. 2014 Jun;32(6):525-31. doi: 10.1007/s40273-014-0162-x.
3
Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.德国药品定价上限设定决策规则：与其他决策规则的比较分析。
Appl Health Econ Health Policy. 2011 Mar 1;9(2):65-71. doi: 10.2165/11586640-000000000-00000.
4
Priority setting of public spending in developing countries: do not try to do everything for everybody.发展中国家公共支出的优先事项设定：不要试图为所有人做所有事。
Health Policy. 2006 Oct;78(2-3):149-56. doi: 10.1016/j.healthpol.2005.10.006. Epub 2005 Nov 21.
Zotero 插件